Literature DB >> 28345383

Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis.

Keith C Meyer1.   

Abstract

INTRODUCTION: Many forms of interstitial lung disease (ILD) can progress to extensive fibrosis and respiratory failure. Idiopathic pulmonary fibrosis (IPF), which generally has a poor prognosis, has been thoroughly studied over the past two decades, and many important discoveries have been made that pertain to genetic predisposition, epidemiology, disease pathogenesis, diagnosis, and management. Additionally, non-IPF forms of ILD can have radiologic and histopathologic manifestations that mimic IPF, and making an accurate diagnosis is key to providing personalized medicine to patients with pulmonary fibrosis. Areas covered: This manuscript discusses current knowledge pertaining to the genetics, epidemiology, pathogenesis, and diagnosis of pulmonary fibrosis with an emphasis on IPF. The material upon which this discussion is based was obtained from various published texts and manuscripts identified via literature searching (e.g. PubMed). Expert commentary: Many genetic variants have been identified that are associated with risk of developing pulmonary fibrosis, and an improved understanding of the influence of both genomic and epigenomic factors in the development of pulmonary fibrosis is rapidly evolving. Because many forms of fibrosing ILD can have similar radiologic and histopathologic patterns yet have different responses to therapeutic interventions, making an accurate diagnosis of specific forms of pulmonary fibrosis is increasingly important.

Entities:  

Keywords:  Pulmonary fibrosis; diagnosis; idiopathic interstitial pneumonia; idiopathic pulmonary fibrosis; interstitial lung disease; treatment; usual interstitial pneumonia

Mesh:

Year:  2017        PMID: 28345383     DOI: 10.1080/17476348.2017.1312346

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  49 in total

1.  tPA promotes the proliferation of lung fibroblasts and activates the Wnt/β-catenin signaling pathway in idiopathic pulmonary fibrosis.

Authors:  Ling Chen; Jiwei Hou; Xiao Fu; Xiang Chen; Jiang Wu; Xiaodong Han
Journal:  Cell Cycle       Date:  2019-09-24       Impact factor: 4.534

Review 2.  Cellular senescence in the lung across the age spectrum.

Authors:  Pavan Parikh; Sarah Wicher; Karl Khandalavala; Christina M Pabelick; Rodney D Britt; Y S Prakash
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-02-20       Impact factor: 5.464

Review 3.  Pulmonary gene delivery-Realities and possibilities.

Authors:  Uday K Baliga; David A Dean
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-12

4.  A nonsynonymous polymorphism (rs117179004, T392M) of hyaluronidase 1 (HYAL1) is associated with increased risk of idiopathic pulmonary fibrosis in Southern Han Chinese.

Authors:  Juan Liu; Yanhan Deng; Zheng Wang; Biwen Mo; Jianghong Wei; Zhenshun Cheng; Qingzhen Peng; Guang Wei; Jingping Li; Ying Shu; Hua Yang; Shirong Fang; Guangwei Luo; Shuo Yang; Yingnan Wang; Jing Zhu; Jingping Yang; Ming Wu; Xuyan Xu; Renying Ge; Xiaoju Zhang; Weining Xiong; Xiaomei Wang; Zongzhe Li
Journal:  J Clin Lab Anal       Date:  2021-05-04       Impact factor: 2.352

5.  MCTR1 Intervention Reverses Experimental Lung Fibrosis in Mice.

Authors:  Jingyi Pan; Xinyu Li; Shengwei Jin; Hui Li; Xinyang Wang; Lili Yang; Houlin Chen; Nana Su; Chenghua Wu; Yu Hao
Journal:  J Inflamm Res       Date:  2021-05-11

Review 6.  Inflammasome as an Effective Platform for Fibrosis Therapy.

Authors:  Ting-Ting Chen; Feng Xiao; Nan Li; Shan Shan; Meng Qi; Zi-Ying Wang; Sheng-Nan Zhang; Wei Wei; Wu-Yi Sun
Journal:  J Inflamm Res       Date:  2021-04-20

Review 7.  Resolution-Based Therapies: The Potential of Lipoxins to Treat Human Diseases.

Authors:  Rafael I Jaén; Sergio Sánchez-García; María Fernández-Velasco; Lisardo Boscá; Patricia Prieto
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

8.  Cymbopogon winterianus Essential Oil Attenuates Bleomycin-Induced Pulmonary Fibrosis in a Murine Model.

Authors:  Lívia A Tavares; Allan A Rezende; Jymmys L Santos; Charles S Estevam; Ana M O Silva; Jaderson K Schneider; John L S Cunha; Daniela Droppa-Almeida; Ivan J Correia-Neto; Juliana C Cardoso; Patricia Severino; Eliana B Souto; Ricardo L C de Albuquerque-Júnior
Journal:  Pharmaceutics       Date:  2021-05-09       Impact factor: 6.321

9.  Mechanism of Yifei Decoction Combined with MitoQ on Inhibition of TGFβ1/NOX4 and PDGF/ROCK Signal Pathway in Idiopathic Pulmonary Fibrosis.

Authors:  Lijuan Chen; Chengzhong Lan; Hong Xiao; Xiaoli Zhang; Xiangrong Qi; Li Ouyang; Yanbin Yang; Fengying Wang; Qihua Jin; Yi Sun
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-28       Impact factor: 2.629

10.  Micellar Hyaluronidase and Spiperone as a Potential Treatment for Pulmonary Fibrosis.

Authors:  Evgenii Skurikhin; Pavel Madonov; Olga Pershina; Natalia Ermakova; Angelina Pakhomova; Darius Widera; Edgar Pan; Mariia Zhukova; Lubov Sandrikina; Andrey Artamonov; Alexander Dygai
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.